Renovorx receives new 510(k) clearance for its renovocath® delivery system designed for targeted treatment of solid tumors

Los altos, calif., sept. 7, 2021 /prnewswire/ --  renovorx , inc. (nasdaq: rnxt), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the u.s. food and drug administration (fda) for its proprietary renovocath delivery system.
RNXT Ratings Summary
RNXT Quant Ranking